Circulating cytokines and angiogenic factors (CAF) as markers of clinical response in the study of trametinib (T) plus gemcitabine (G) versus placebo (P) plus gemcitabine for patients (pts) with untreated metastatic adenocarcinoma of the pancreas (MEK113487).
John Heymach
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Hai T. Tran
No relevant relationships to disclose
Andrew B. Nixon
Consultant or Advisory Role - GlaxoSmithKline
Herbert Hurwitz
Consultant or Advisory Role - Bayer; Regeneron; Roche/Genentech; Sanofi
Honoraria - Roche/Genentech
Research Funding - Lilly; Regeneron; Roche/Genentech; Sanofi
Jeffrey R. Infante
Consultant or Advisory Role - GlaxoSmithKline (U)
Robert C. Gagnon
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Klaudia Steplewski
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Ngocdiep T. Le
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Yuan Liu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline